Metastatic Melanoma of Uncertain Primary with 5-Year Durable Response after Conventional Therapy: A Case Report with Literature Review.

about

Metastatic Melanoma of Uncertain Primary with 5-Year Durable Response after Conventional Therapy: A Case Report with Literature Review.

Item

http://www.wikidata.org/entity/Q55372822

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Metastatic Melanoma of Uncerta ...... Report with Literature Review.

@en

Metastatic Melanoma of Uncerta ...... Report with Literature Review.

@nl

type

Item

label

Metastatic Melanoma of Uncerta ...... Report with Literature Review.

@en

Metastatic Melanoma of Uncerta ...... Report with Literature Review.

@nl

prefLabel

Metastatic Melanoma of Uncerta ...... Report with Literature Review.

@en

Metastatic Melanoma of Uncerta ...... Report with Literature Review.

@nl

P1476

Metastatic Melanoma of Uncerta ...... Report with Literature Review.

@en

P2093

Jitsupa Treetipsatit

http://www.w3.org/2001/XMLSchema#string

P2860

Immunologic correlates of the abscopal effect in a patient with melanoma

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib

Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies.

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.

Multiple pathways to tumor immunity and concomitant autoimmunity.

Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.

Therapeutic implications of autoimmune vitiligo T cells.

Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.

P304

7289896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1155/2018/7289896

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

J Chantharasamee

P577

2018-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29955408

http://www.w3.org/2001/XMLSchema#string

P932

6000835

http://www.w3.org/2001/XMLSchema#string